Patterns of recurrence after curative resection of pancreatic ductal adenocarcinoma
Introduction
It remains a challenge to improve the survival of patients with pancreatic ductal adenocarcinoma (PDAC). The majority of patients present with locally advanced or metastatic disease and have a median survival of 6–8 months irrespective of the type of treatment modality.1 In selected patients (5–15%) with localised PDAC, surgical resection is the only treatment offering long-time survival.2 Despite the curative intent of surgical resection, cancer recurrence develops within two years after pancreatic surgery in over 60% of patients.3
Multiple studies have investigated the predictors of survival after surgery. However, only a few variables have been shown to correlate consistently with patient outcome. Surgical resection margin status and the presence of lymph node metastases were found to be most important determinants of survival after surgery for PDAC.2, 4, 5, 6 Although the majority of patients with PDAC die from distant metastatic disease, little is known about the exact pattern of cancer recurrence. The aim of the present study is to determine the first localization of cancer recurrence and the time interval to develop recurrence following curative resection of PDAC. A better understanding of the patterns of failure, i.e. where and when cancer recurrence occurs, could help develop novel and more rational therapeutic approaches.
Section snippets
Patients
Between January 1998 and December 2005, one hundred and forty-five patients with PDAC underwent surgical resection with curative intent. Patients with an intraductal papillary mucinous tumour (IPMT) were excluded from the study. The male/female ratio was 75/70, with a median age of 67 years (range 32–85 y). A standard pancreaticoduodenectomy (PD; n = 73) or a pylorus-preserving procedure (PPPD; n = 48) was performed in 121 patients for ductal carcinoma of the pancreatic head. Patients with PDAC of
Results
Median (range) duration of surgery was 258 (100–480) min, with a median intra-operative blood loss of 1100 (100–5000) ml. Postoperative complications occurred in 82 patients, with subsequent hospital mortality in 6 patients. Postoperative pancreatic fistula developed in 15 patients.
Discussion
In the present study, the recurrence rate after curative surgery for PDAC was 56.7, 76.6, and 84.1% at 1, 2, and 5 years, respectively. Over 90% of patients developed cancer recurrence in the abdominal cavity as being the first site of localization, either isolated or combined, in the liver (39%), locoregional (30%), or the peritoneum (24%). Pulmonary metastases occurred in about 10% of the patients and represented the most frequent site of extra-abdominal recurrence. Recurrence rates in the
Conclusion
After curative surgery for PDAC most patients develop locoregional and distant cancer recurrence, and survival rates remain low. The vast majority of patients develop cancer recurrence within the abdominal cavity. Surgical resection margins with tumour involvement (pR1) and tumour-free margins of less then 1 mm are negative prognostic factors. At present, adjuvant chemotherapy is the only adjuvant treatment with a small survival benefit, but really effective adjuvant treatment is lacking.
Conflict of interest
The authors have no conflict of interest.
Acknowledgements
Many thanks to the staff members of the departments of hepatobiliary and pancreatic diseases, digestive oncology, radiotherapy, and radiology for inclusion and follow-up of patients into this study; C. Verslype, E. Van Cutsem, K. Haustermans, D. Bielen, and D. Vanbeckevoort, respectively.
References (23)
- et al.
Detection and prognostic impact of disseminated tumor cells in pancreatic carcinoma
Pancreatology
(2002) Exocrine pancreas. American Joint Committee on Cancer: AJCC Cancer Staging Manual
(2002)- et al.
Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma
Br J Surg
(2004) - et al.
Patterns of failure after curative resection of pancreatic carcinoma
Cancer
(1990) - et al.
A margin-negative R0 resection accomplished with minimal postoperative complications is the surgeon's contribution to long-term survival in pancreatic cancer
J Gastrointest Surg
(2006) - et al.
1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience
J Gastrointest Surg
(2006) - et al.
The prognostic significance of lymph node metastasis and intrapancreatic perineural invasion in pancreatic cancer after curative resection
Surg Today
(1999) - et al.
The determinant factors of recurrence following resection for ductal pancreatic cancer
JOP
(2007) - et al.
Recurrence of exocrine pancreatic cancer – local or hepatic?
Hepatogastroenterology
(1993) - et al.
Aggressive surgery for pancreatic duct cell cancer: feasibility, validity, limitations
World J Surg
(1995)
An Evaluation of radical resection for pancreatic cancer based on the mode of recurrence as determined by autopsy and diagnostic imaging
Cancer
Cited by (261)
Stereotactic body radiotherapy for pancreatic cancer – A systematic review of prospective data
2024, Clinical and Translational Radiation OncologyHigh-risk liver patients are not associated with adverse events following pancreaticoduodenectomy
2023, American Journal of SurgeryClinicopathological variables and risk factors for lung recurrence after resection of pancreatic ductal adenocarcinoma
2023, Asian Journal of SurgeryMetastatic pulmonary adenocarcinoma after 20 years of primary pancreatic adenocarcinoma resection: A case report and literature review
2022, Annals of Medicine and Surgery